Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Assets Average (2016 - 2025)

Coherus Oncology's Assets Average history spans 12 years, with the latest figure at $387.4 million for Q4 2025.

  • For Q4 2025, Assets Average fell 18.74% year-over-year to $387.4 million; the TTM value through Dec 2025 reached $387.4 million, down 18.74%, while the annual FY2025 figure was $353.4 million, 34.44% down from the prior year.
  • Assets Average for Q4 2025 was $387.4 million at Coherus Oncology, down from $478.0 million in the prior quarter.
  • Across five years, Assets Average topped out at $767.5 million in Q1 2021 and bottomed at $387.4 million in Q4 2025.
  • The 5-year median for Assets Average is $559.1 million (2022), against an average of $569.0 million.
  • The largest annual shift saw Assets Average surged 75.33% in 2021 before it tumbled 43.65% in 2025.
  • A 5-year view of Assets Average shows it stood at $710.5 million in 2021, then fell by 27.4% to $515.9 million in 2022, then increased by 17.6% to $606.7 million in 2023, then fell by 21.42% to $476.8 million in 2024, then dropped by 18.74% to $387.4 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Assets Average are $387.4 million (Q4 2025), $478.0 million (Q3 2025), and $405.3 million (Q2 2025).